ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Subscribe To Our Newsletter & Stay Updated
